Leo Cancer Care Brings Into Clinical Use an Upright Radiotherapy Platform Cleared for Use With Any Radiation Beam
Image File
Original HTML

Upright. From Concept to Clinical Reality

BOSTON, Sept. 27, 2026 /PRNewswire/ -- Leo Cancer Care is marking a defining moment for radiation oncology as upright radiotherapy moves from concept to clinical reality.

The Upright Platform is designed to be beam-agnostic and cleared for integration with both particle- and photon-compatible fixed-beam technologies, offering health networks unprecedented choice rather than being restricted to one beam manufacturer or treatment configuration.

A Flexible, Now Clinically Available Platform Built for the Future

Following the first clinical treatment using Leo Cancer Care's Marie® upright patient positioning and imaging system in June 2026, patients can now receive radiotherapy in an upright position. Enabled by a partnership with Mevion Medical System, utilising their compact, fixed-beam proton accelerator and powered by RayStation®, the treatment planning system from RaySearch Laboratories.

While this represents an important clinical milestone, the potential of Leo Cancer Care's upright technology extends beyond one installation or treatment configuration. Its flexible platform creates opportunities for clinicians and technology partners to explore compliant IGRT system combinations around the needs of their patients, infrastructure and services.

Expanding Access to Upright Photon Radiotherapy

While Leo Cancer Care's initial product offering, the Marie® solution, is 510(k) cleared and CE marked to be integrated with any fixed beam, including conventional photon therapy, the company revealed development of a dedicated fixed-beam photon platform of its own (subject to regulatory clearance), at ASTRO 2025. This platform would integrate upright patient positioning, imaging and a fixed photon beam. Treating with photons in the upright position has the potential to offer greater patient choice while enabling more compact radiotherapy solutions that could help expand access to high-quality cancer care.

This next future innovation represents an important step towards bringing upright positioning and imaging into conventional radiotherapy and changing how photon treatment services are designed and delivered. This new method is already being utilized in new proton therapy installations where health networks are adopting a treatment delivery solution that was not so long ago widely questioned.

One Upright Environment. One Consistent Workflow. A Single Source of Truth.

Leo Cancer Care has taken a fundamentally different approach to radiotherapy. The radiation beam remains fixed while the patient is positioned upright and slowly rotated to multiple beam angles, enabling radiation to be delivered around the target area to deliver their personalised treatment plan.

At the heart of the solution is the upright platform, connecting fan beam imaging, planning, positioning and treatment delivery around a single patient position. Because the patient is imaged in the position they are treated in, every stage of the pathway works from the same geometry, giving the clinical team one reference point to plan and verify against.

For patients, upright radiotherapy provides a treatment experience centred around a more natural position, with eye-to-eye interaction with the clinical team. It may be particularly valuable for people who find it difficult or uncomfortable to lie flat because of breathing difficulties, pain, mobility challenges or anxiety.

International research also suggests that upright positioning may support more consistent anatomical positioning and reduce organ motion for certain treatment sites. These potential benefits will continue to be investigated as more upright systems enter research and clinical use.

From Innovation to Adoption

Stephen Towe, Co-Founder and CEO of Leo Cancer Care said: "The first clinical treatment using our technology proved that upright radiotherapy is no longer simply an idea for the future. It is now a clinical reality. This milestone is only the beginning. By connecting imaging, planning, positioning and treatment delivery in the upright position, we can create a single source of truth throughout the patient's treatment journey. Our beam-agnostic approach gives us the flexibility to work with different compatible fixed-beam technologies, helping reduce the infrastructure traditionally associated with advanced radiotherapy and supporting our ambition to expand access to high-quality cancer care."

At the American Society for Radiation Oncology's 2026 Annual Meeting in Boston, Leo Cancer Care will share its clinical progress and vision for the future.

The next phase will focus on building clinical evidence, supporting further installations and collaborating with healthcare and technology partners to make advanced treatment more human and accessible.

Natural anatomy. New possibilities. Think Upright.

SOURCE Leo Cancer Care

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Need Review
Dedupe hash
prn_302890849
Press Eligible
Yes
Press Eligible Reason
QA FAIL (need review): TARGET contains factual claims not in SOURCE: it describes the milestone as a shift to 'routine clinical use' (SOURCE only says first treatment, making upright radiotherapy a 'clinical reality'), and it claims the system 'aims to reduce setup errors' (SOURCE mentions a shared geometry/reference point but never mentions setup errors).
Source Name
Unknown Company
Original Summary

<p>Upright. From Concept to Clinical Reality BOSTON, Sept. 27, 2026 /PRNewswire/ -- Leo Cancer Care is marking a defining moment for radiation oncology as upright radiotherapy moves from concept to clinical reality. The Upright Platform is designed to be beam-agnostic and cleared for...</p>

Original Link
Original Source
Image URL
https://mmx.prnewswire.com/media/MS1698370/Leo-Cancer-Care-Logo.jpg?id=OA2972484&p=facebook
Generated Article_json
{"target_audience": "b2b", "is_medical": true, "ai_generated_title": "Leo Cancer Care Completes First Clinical Upright Radiotherapy Treatment", "body_html": "<p><strong>Boston – [CURRENT_DATE] --</strong> Leo Cancer Care has completed the first clinical treatment using its Marie upright patient positioning and imaging system, marking the shift of upright radiotherapy from concept to routine clinical use.</p><h5>First patient treated upright in June 2026 using proton therapy</h5><p>The milestone treatment, delivered in June 2026, combined Leo Cancer Care's Marie system with Mevion Medical Systems' compact fixed-beam proton accelerator and RayStation, the treatment planning software from RaySearch Laboratories. The Marie platform is 510(k) cleared and CE marked for integration with any fixed-beam technology, including conventional photon therapy.</p><h5>Beam-agnostic design lets health networks avoid single-vendor lock-in</h5><p>Rather than tying hospitals to one beam manufacturer, the Upright Platform is built to interoperate with both particle- and photon-compatible fixed-beam systems. The company positions this flexibility as a way to cut the infrastructure typically required for advanced radiotherapy while widening the pool of compatible technology partners.</p><h5>Dedicated photon platform in development following ASTRO 2025 announcement</h5><p>Leo Cancer Care confirmed at ASTRO 2025 that it is developing its own fixed-beam photon platform, integrating upright positioning, imaging and a photon beam into a single system, subject to future regulatory clearance. The company argues upright photon delivery could enable more compact treatment rooms and expand access to high-quality cancer care in networks unable to support larger fixed-beam installations.</p><h5>Single imaging position aims to reduce setup errors across the treatment pathway</h5><p>The system keeps the radiation beam stationary while rotating the patient upright through multiple beam angles. Because imaging and treatment occur in the same position, clinical teams work from one consistent geometric reference point for planning and verification, rather than reconciling data captured in different postures.</p><p>International research cited by the company suggests upright positioning may improve anatomical consistency and reduce organ motion for certain treatment sites, an area it says will require further clinical investigation as more systems enter use.</p><h5>CEO says beam-agnostic approach reduces infrastructure burden on providers</h5><p>Stephen Towe, Co-Founder and CEO of Leo Cancer Care, said the first clinical treatment proved upright radiotherapy is now a clinical reality rather than a future concept, and that the company's flexibility to work across compatible fixed-beam technologies supports its ambition to expand access to advanced cancer care.</p><p>Leo Cancer Care is presenting its clinical progress at the American Society for Radiation Oncology's 2026 Annual Meeting in Boston, with its next phase focused on building clinical evidence, supporting additional installations, and working with healthcare and technology partners on further deployments.</p>", "meta_description": "Leo Cancer Care completes first clinical upright radiotherapy treatment with Mevion and RaySearch, advancing a beam-agnostic platform toward wider hospital adoption.", "seo_keywords": "upright radiotherapy, Leo Cancer Care, Marie system, Mevion Medical Systems, RaySearch Laboratories, proton therapy, ASTRO 2026, radiation oncology", "companies": ["Leo Cancer Care", "Mevion Medical Systems", "RaySearch Laboratories"], "industries": ["Healthcare & Biotech"], "markets_regions": ["North America", "United States"], "news_type": ["product_launch", "regulatory_update"], "products": ["Upright Platform"], "themes": ["medical_technology", "clinical_innovation", "patient_care"], "events": ["ASTRO 2026 Annual Meeting"], "cta_text": "Details on Leo Cancer Care's upright radiotherapy platform and clinical roadmap are available from the company.", "learn_more": "", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}
Content Hash (SHA-256, erste 32 hex)
ac62e550e7ad51d7fd4f3a8fe5f61a6e